Explore

Vox Vox
The worst kind of cancer suddenly isn’t so scary anymore

The worst kind of cancer suddenly isn’t so scary anymore

Scientists have made astonishing progress in treating one of the deadliest cancers.
Trendline Trendline
ImmunityBio Reports Positive Data for Bladder Cancer Treatment at AUA 2026

ImmunityBio Reports Positive Data for Bladder Cancer Treatment at AUA 2026

ImmunityBio Reports Positive Data for Bladder Cancer Treatment at AUA 2026
Trendline Trendline
Upsher-Smith Launches Generic Cyclosporine Ophthalmic Emulsion, Expanding U.S. Market Offerings

Upsher-Smith Launches Generic Cyclosporine Ophthalmic Emulsion, Expanding U.S. Market Offerings

Upsher-Smith Launches Generic Cyclosporine Ophthalmic Emulsion, Expanding U.S. Market Offerings
Trendline Trendline
Galvanize Therapeutics Gains FDA Clearance for Aliya EX Generator, Enhancing Surgical Ablation Options

Galvanize Therapeutics Gains FDA Clearance for Aliya EX Generator, Enhancing Surgical Ablation Options

Galvanize Therapeutics Gains FDA Clearance for Aliya EX Generator, Enhancing Surgical Ablation Options
Trendline Trendline
Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis
Trendline Trendline
PorTal Access, Inc. Completes FDA 510(k) Submission for Flexi-Port, Paving Way for Oncology Device Launch

PorTal Access, Inc. Completes FDA 510(k) Submission for Flexi-Port, Paving Way for Oncology Device Launch

PorTal Access, Inc. Completes FDA 510(k) Submission for Flexi-Port, Paving Way for Oncology Device Launch
Trendline Trendline
Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead
Trendline Trendline
ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Bladder Cancer

ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Bladder Cancer

ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Bladder Cancer
Trendline Trendline
FDA Approval of Regeneron's Otarmeni Marks Progress in Gene Therapies for Hearing Loss

FDA Approval of Regeneron's Otarmeni Marks Progress in Gene Therapies for Hearing Loss

FDA Approval of Regeneron's Otarmeni Marks Progress in Gene Therapies for Hearing Loss
Trendline Trendline
PorTal Access Completes FDA Submission for Flexi-Port, Paving Way for Launch

PorTal Access Completes FDA Submission for Flexi-Port, Paving Way for Launch

PorTal Access Completes FDA Submission for Flexi-Port, Paving Way for Launch
Trendline Trendline
Empirical Spine Launches LimiFlex as Motion-Preserving Alternative for Spinal Fusion in U.S.

Empirical Spine Launches LimiFlex as Motion-Preserving Alternative for Spinal Fusion in U.S.

Empirical Spine Launches LimiFlex as Motion-Preserving Alternative for Spinal Fusion in U.S.
Trendline Trendline
CEL-SCI Reports Progress in Multikine Development and Financial Results

CEL-SCI Reports Progress in Multikine Development and Financial Results

CEL-SCI Reports Progress in Multikine Development and Financial Results